IMMUNITYBIO, INC. Deferred Tax Assets, Operating Loss Carryforwards, Foreign
IMMUNITYBIO, INC. (IBRX) had Deferred Tax Assets, Operating Loss Carryforwards, Foreign of $22.00 million as of 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign · last filed 2026-02-23
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $22.00M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $16.30M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $14.30M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $10.10M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Foreign |
|---|---|
| 2025-12-31 | $22.00M 10-K · filed 2026-02-23 |
| 2024-12-31 | $16.30M 10-K · filed 2025-03-03 |
| 2023-12-31 | $14.30M 10-K · filed 2024-03-19 |
| 2022-12-31 | $10.10M 10-K · filed 2023-03-01 |
| 2021-12-31 | $8.00M 10-K · filed 2022-03-01 |
| 2016-12-31 | $28.00K 10-K · filed 2017-03-15 |
| 2015-12-31 | $40.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |